Health Technology Assessment Policy and Methods Review

Consultation plan

Our stakeholders represent a diverse range of individuals and groups with a broad range of experiences and knowledge. The consultation activities have been planned to ensure that all stakeholders are able to meaningfully and constructively contribute to the Review so that the Reference Committee has a well-informed understanding of issues and perspectives to inform its recommendations to Government.

Planned consultation for the Review includes several opportunities for stakeholders to get involved at different phases through a variety of methods to ensure accessibility for the diverse needs and preferences of stakeholders. For further details on how to get involved or to make accessibility arrangements to be able to participate, please email HTAReviewConsult@health.gov.au

	Timing	Goals	Key stakeholders	Method/s	Notification
Consultation 1 (C1)	Open for 8 weeks From 11 April 2023	This phase seeks broad engagement to provide early guidance into the Review focused on the key objectives.	Open for all stakeholders to participate, including (but not limited to): • Patients and consumers • Clinicians and clinical groups • Industry • HTA Evaluators, research, and academic groups • States and Territory Governments • Federal Government Departments • Not for Profit and Non-Government Organisations	The process will seek responses to questions designed to guide submissions in line with the objectives as defined in the ToR through: • Written online submission • Webex forums	Consultation hub, Health website, Pharmaceutical Benefits Scheme (PBS) news item, and email notifications to known key stakeholders.
Consultation deep dives (CDD)	Throughout the Review Date to be confirmed (Early May 2023)	This phase seeks to gain an in-depth understanding for specific complex topics, issues, challenges, and opportunities for HTA.	It will target stakeholders with in-depth knowledge or understanding on a topic or issue highly relevant to the review, including (but not limited to): • Patients and consumers • HTA Experts • Parallel policy reform areas • International counterparts • Clinical and academic groups • Industry	This process will involve a combination of in-person discussions, Webex and written submissions as agreed by the Reference Committee.	An EOI will be open on consultation hub. Topics and stakeholders agreed by the Reference Committee will be contacted directly.
Consultation 2 (C2)	Open for 8 weeks Date to be confirmed (Early October 2023)	This phase will workshop options with stakeholders to understand potential implications and identify unintended outcomes.	Open for all stakeholders to participate, including (but not limited to): • Patients and consumers • Clinicians and clinical groups • Industry • HTA Evaluators, research, and academic groups • States and Territory Governments • Federal Government Departments • Not for Profit and Non-Government Organisations	This process will seek responses to draft options developed by the Reference Committee, through: • Written online submission • Webex workshops / group forums • In person workshops / group forums	Consultation hub, Health website, Pharmaceutical Benefits Scheme (PBS) news item, and email notifications to known key stakeholders.

Timelines and Key Milestones



Note: Date for Consultation 2 and consultation deep dives are indicative only. More information including exact dates will be released as the Review progresses.

Subscribe to PBS news at www.pbs.gov.au to receive notifications of additional details throughout the Review.